Real-World First-Line Use of Pertuzumab With Different Taxanes for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer: A Comparative Effectiveness Study Using US Electronic Health Records.
Letizia PolitoJinjoo ShimSara Alsterlind HurvitzChau T DangAdam KnottYolande du ToitEleonora RestucciaThibaut SanglierSandra M SwainPublished in: JCO oncology practice (2023)
There was no statistically significant difference in real-world outcomes between patients treated with paclitaxel/nab-paclitaxel and those treated with docetaxel. Selecting patients using key CLEOPATRA eligibility criteria resulted in rwPFS and rwOS similar to those observed in CLEOPATRA, highlighting the importance of ensuring similar patient populations when comparing clinical trial and real-world data.
Keyphrases
- epidermal growth factor receptor
- electronic health record
- metastatic breast cancer
- advanced non small cell lung cancer
- clinical trial
- end stage renal disease
- tyrosine kinase
- newly diagnosed
- endothelial cells
- clinical decision support
- ejection fraction
- prognostic factors
- peritoneal dialysis
- chronic kidney disease
- adverse drug
- big data
- randomized controlled trial
- machine learning
- locally advanced
- patient reported outcomes
- radiation therapy
- study protocol
- squamous cell carcinoma
- type diabetes
- metabolic syndrome
- insulin resistance